1. |
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2024, 74(3): 229-263.
|
2. |
Lei S, Zheng R, Zhang S, et al. Global patterns of breast cancer incidence and mortality: a population-based cancer registry data analysis from 2000 to 2020. Cancer Commun (Lond), 2021, 41(11): 1183-1194.
|
3. |
Katsura C, Ogunmwonyi I, Kankam HK, et al. Breast cancer: presentation, investigation and management. Br J Hosp Med (Lond), 2022, 83(2): 1-7.
|
4. |
Kolak A, Kamińska M, Sygit K, et al. Primary and secondary prevention of breast cancer. Ann Agric Environ Med, 2017, 24(4): 549-553.
|
5. |
Michaels E, Worthington RO, Rusiecki J. Breast cancer: risk assessment, screening, and primary prevention. Med Clin North Am, 2023, 107(2): 271-284.
|
6. |
Britt KL, Cuzick J, Phillips KA. Key steps for effective breast cancer prevention. Nat Rev Cancer, 2020, 20(8): 417-436.
|
7. |
Bevers TB, Helvie M, Bonaccio E, et al. Breast cancer screening and diagnosis, version 3. 2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 2018, 16(11): 1362-1389.
|
8. |
Benitez Fuentes JD, Morgan E, de Luna Aguilar A, et al. Global stage distribution of breast cancer at diagnosis: a systematic review and meta-analysis. JAMA Oncol, 2024, 10(1): 71-78.
|
9. |
Wang X, Wang C, Guan J, et al. Progress of breast cancer basic research in China. Int J Biol Sci, 2021, 17(8): 2069-2079.
|
10. |
陈万青, 李霓, 石菊芳, 等. 中国城市癌症早诊早治项目进展. 中国肿瘤, 2019, 28(1): 23-25.
|
11. |
黄静, 杨湘红, 刘爱, 等. 农村地区妇女“两癌筛查”项目实施中的问题与对策. 中国全科医学, 2020, 23(13): 1680-1686.
|
12. |
Harbeck N, Penault-Llorca F, Cortes J, et al. Breast cancer. Nat Rev Dis Primers, 2019, 5(1): 66. doi: 10.1038/s41572-019-0111-2.
|
13. |
Nguyen TL, Li S, Dite GS, et al. Interval breast cancer risk associations with breast density, family history and breast tissue aging. Int J Cancer, 2020, 147(2): 375-382.
|
14. |
Pfeiffer RM, Webb-Vargas Y, Wheeler W, et al. Proportion of U. S. trends in breast cancer incidence attributable to long-term changes in risk factor distributions. Cancer Epidemiol Biomarkers Prev, 2018, 27(10): 1214-1222.
|
15. |
Rudel RA, Fenton SE, Ackerman JM, et al. Environmental exposures and mammary gland development: state of the science, public health implications, and research recommendations. Environ Health Perspect, 2011, 119(8): 1053-1061.
|
16. |
Terry MB, Colditz GA. Epidemiology and risk factors for breast cancer: 21st century advances, gaps to address through interdisciplinary science. Cold Spring Harb Perspect Med, 2023, 13(9): a041317. doi: 10.1101/cshperspect.a041317.
|
17. |
Vaz-Luis I, Partridge AH. Exogenous reproductive hormone use in breast cancer survivors and previvors. Nat Rev Clin Oncol, 2018, 15(4): 249-261.
|
18. |
Tao X, Li T, Gandomkar Z, et al. Incidence, mortality, survival, and disease burden of breast cancer in China compared to other developed countries. Asia Pac J Clin Oncol, 2023, 19(6): 645-654.
|
19. |
Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China. Lancet Oncol, 2014, 15(7): e279-e289.
|
20. |
赫捷, 陈万青, 李霓, 等. 中国女性乳腺癌筛查与早诊早治指南 (2021, 北京). 中国肿瘤, 2021, 30(3): 161-191.
|
21. |
Jing S, Zhang A, Chen Y, et al. Mindfulness-based interventions for breast cancer patients in China across outcome domains: a systematic review and meta-analysis of the Chinese literature. Support Care Cancer, 2021, 29(10): 5611-5621.
|
22. |
Kobayashi S, Sugiura H, Ando Y, et al. Reproductive history and breast cancer risk. Breast Cancer, 2012, 19(4): 302-308.
|
23. |
Nounu A, Kar SP, Relton CL, et al. Sex steroid hormones and risk of breast cancer: a two-sample Mendelian randomization study. Breast Cancer Res, 2022, 24(1): 66. doi: 10.1186/s13058-022-01553-9.
|
24. |
Rojas K, Stuckey A. Breast cancer epidemiology and risk factors. Clin Obstet Gynecol, 2016, 59(4): 651-672.
|
25. |
Russo J. Reproductive history and breast cancer prevention. Horm Mol Biol Clin Investig, 2016, 27(1): 3-10.
|
26. |
Yuan XM, Wang N, Ouyang T, et al. Current status of diagnosis and treatment of primary breast cancer in beijing, 2008. Chin J Cancer Res, 2011, 23(1): 38-42.
|
27. |
包鹤龄, 王临虹, 王丽敏, 等. 中国2013年35~69岁女性人群子宫颈癌和乳腺癌筛查率及影响因素研究. 中华流行病学杂志, 2018, 39(2): 208-212.
|
28. |
Breen N, Gentleman JF, Schiller JS. Update on mammography trends: comparisons of rates in 2000, 2005, and 2008. Cancer, 2011, 117(10): 2209-2218.
|
29. |
莫淼, 袁晶, 周昌明, 等. 以大型单中心的医院登记为基础的3. 5万例乳腺癌患者长期生存报告. 中国癌症杂志, 2020, 30(2): 90-97.
|
30. |
瞿亚军, 吕青. 我国乳腺癌预防若干问题的思考. 中国普外基础与临床杂志, 2020, 27(11): 1334-1339.
|
31. |
Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet, 2018, 391(10125): 1023-1075.
|
32. |
Loibl S, Poortmans P, Morrow M, et al. Breast cancer. Lancet, 2021, 397(10286): 1750-1769.
|
33. |
Ren W, Chen M, Qiao Y, et al. Global guidelines for breast cancer screening: a systematic review. Breast, 2022, 64: 85-99.
|
34. |
Li J, Jiang Z. Antibody drug conjugates in breast cancer in China: highlights, challenges, and prospects. Cancer, 2024, 130(S8): 1371-1377.
|
35. |
曹毛毛, 陈万青. 中国恶性肿瘤流行情况及防控现状. 中国肿瘤临床, 2019, 46(3): 145-149.
|
36. |
吕青, 瞿亚军. 乳腺良性疾病与乳腺癌风险. 中国普外基础与临床杂志, 2020, 27(11): 1329-1333.
|